The chief medical officer of Passage Bio discussed research needs in FTD.
Mark Forman, MD, PhD
Advertisement
Articles by Mark Forman, MD, PhD
The chief medical officer of Passage Bio discussed the phase 1/2 upliFT-D study of PBFT02.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Sangamo Starts Putting BLA for Fabry Disease Gene Therapy Isa-Vec in Front of FDA
2
What the Field of Cell and Gene Therapy Needs Most in the Current Moment
3
CGTLive®’s Weekly Rewind – December 19, 2025
4
The Implications of the Final Data From Hemgenix’s HOPE-B Trial
5